Keyphrases
Uterine Cervix
100%
Management Options
100%
Acute Myeloid Leukemia
100%
Glomus Tumor
100%
Myeloproliferative Neoplasms
100%
De Novo Acute Myeloid Leukemia
100%
JAK2V617F
100%
Adjuvant Therapy
66%
Cervical Dysplasia
66%
Early Disease
66%
Tumor
66%
Pathologic Characteristics
33%
Tumor Necrosis
33%
Clinical Benefit
33%
Histologic
33%
Advanced Disease
33%
Leiomyosarcoma
33%
Oophorectomy
33%
Malignancy-associated
33%
Cytological Atypia
33%
Tumor Cells
33%
Similar Cases
33%
Clinical Trials
33%
Multidrug-resistant
33%
Lymph Node Dissection
33%
Small Caliber
33%
Targeted Therapy
33%
Uterine Sarcoma
33%
Epithelioid Cells
33%
Histologic Examination
33%
Epidemiology
33%
Desmin
33%
Submucosa
33%
Complete Surgical Resection
33%
Blood Vessels
33%
Overall Survival
33%
CD34
33%
Clinical Presentation
33%
Surgical Resection
33%
Mitotic Index
33%
Nivolumab
33%
Pembrolizumab
33%
High-grade Squamous Intraepithelial Lesion
33%
Hysterectomy
33%
Management Strategy
33%
α-smooth muscle Actin (α-SMA)
33%
Mesenchymal Tumor
33%
Incidental
33%
Most Common Form
33%
Older Women
33%
Medicine and Dentistry
Glomus Tumor
100%
Acute Myeloid Leukemia
100%
Myeloproliferative Neoplasm
100%
Uterine Cervix
100%
De Novo Acute Myeloid Leukemia
100%
Leiomyosarcoma
100%
Janus Kinase
100%
Neoplasm
83%
Uterine Cervix Dysplasia
66%
Adjuvant Therapy
50%
Diseases
50%
Surgery
50%
Vascular Bundle
33%
Desmin
33%
Submucosa
33%
Epithelioid Cell
33%
Tumor Cell
33%
Smooth Muscle Actin
33%
Mitotic Index
25%
Retroperitoneal Lymph Node Dissection
25%
Targeted Therapy
25%
Chemotherapy
25%
Recurrent Disease
25%
Tumor Necrosis
25%
Hysterectomy
25%
Ovariectomy
25%
Nivolumab
25%
Immunotherapy
25%
Cohort Effect
25%
Pembrolizumab
25%
Overall Survival
25%
Clinical Trial
25%
Cancer
25%
Pazopanib
25%
Acute Myelogenous Leukemia
13%
Karyotype
13%
Induction Chemotherapy
6%
Splenomegaly
6%
DNA Methylation
6%
Philadelphia 1 Chromosome
6%
Morphology
6%
Megakaryocyte
6%